CryoPort (NASDAQ:CYRX) Insider Edward Zecchini Sells 2,014 Shares

CryoPort, Inc. (NASDAQ:CYRX) insider Edward Zecchini sold 2,014 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $8.00, for a total transaction of $16,112.00. Following the completion of the sale, the insider owned 109,719 shares of the company’s stock, valued at $877,752. This trade represents a 1.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

CryoPort Stock Performance

Shares of NASDAQ CYRX traded up $0.36 during mid-day trading on Tuesday, hitting $8.36. 401,705 shares of the stock traded hands, compared to its average volume of 429,763. The company has a market cap of $416.83 million, a price-to-earnings ratio of 6.33 and a beta of 1.69. The stock has a fifty day moving average price of $9.19 and a 200-day moving average price of $9.36. CryoPort, Inc. has a 52 week low of $4.63 and a 52 week high of $11.45.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). CryoPort had a net margin of 42.35% and a negative return on equity of 8.22%. The business had revenue of $45.45 million for the quarter, compared to analysts’ expectations of $42.92 million. As a group, sell-side analysts predict that CryoPort, Inc. will post -0.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Wall Street Zen lowered shares of CryoPort from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Needham & Company LLC upped their price target on CryoPort from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of CryoPort in a research note on Monday, December 29th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $12.94.

Institutional Trading of CryoPort

A number of institutional investors and hedge funds have recently bought and sold shares of CYRX. AQR Capital Management LLC raised its holdings in CryoPort by 285.5% in the first quarter. AQR Capital Management LLC now owns 262,596 shares of the company’s stock worth $1,597,000 after buying an additional 194,482 shares during the last quarter. Savant Capital LLC purchased a new stake in shares of CryoPort during the second quarter valued at approximately $93,000. ProShare Advisors LLC bought a new stake in shares of CryoPort during the second quarter valued at approximately $75,000. Geode Capital Management LLC raised its holdings in CryoPort by 7.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,203,061 shares of the company’s stock worth $8,977,000 after acquiring an additional 87,418 shares during the last quarter. Finally, Creative Planning purchased a new position in CryoPort in the 2nd quarter worth approximately $96,000. 92.90% of the stock is currently owned by institutional investors.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.